Information Provided By:
Fly News Breaks for March 4, 2020
EOLS
Mar 4, 2020 | 15:07 EDT
Mizuho analyst Vamil Divan notes that Evolus issued a statement addressing comments in the Korean media related to ongoing litigation between their partner Daewoong and competitor Medytox. While it appears Medytox has leaked some confidential staff attorney briefings to the Korean press, it is not clear how meaningful this information actually is as it relates to the judge's initial determination on the case or the ITC's crucial final decision, he notes. Divan continues to see value in Evolus at current levels given the progress it is making with Jeuveau's launch in the facial aesthetics market, but appreciates new investors in particular may remain concerned with the legal overhang. The analyst has a Buy rating and a $20 price target on the shares.
News For EOLS From the Last 2 Days
EOLS
Apr 22, 2021 | 08:54 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Renalytix... To see the rest of the story go to thefly.com. See Story Here
EOLS
Apr 21, 2021 | 18:51 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGSQualtrics... To see the rest of the story go to thefly.com. See Story Here
EOLS
Apr 21, 2021 | 16:02 EDT
SVB Leerink, Stifel and Cantor are acting as joint bookrunning managers for the offering.